Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 10/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579830 | 0.84 | HSP90AA1 (0.40) | CYP17A1CYP1A2PLK4PDE2ACNR2 | |
| SCHEMBL25876223 | 0.81 | PDE2A (0.40) | CYP1A2PDE2A | |
| SCHEMBL25875949 | 0.81 | ADORA3 (0.42) | CYP1A2PDE2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL19838242 | 0.79 | PDE2A (0.45) | CYP17A1CYP1A2PLK4PDE2APIK3CA | |
| SCHEMBL25875979 | 0.79 | PDE2A (0.35) | PDE2A | |
| SCHEMBL25876283 | 0.78 | PDE1A (0.44) | PDE2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25876067 | 0.75 | PDE1A (0.41) | PDE2AALDH1A1 | |
| SCHEMBL60944 | 0.74 | JAK1 (0.37) | PDE2APIK3CAMTOR | |
| SCHEMBL3989353 | 0.73 | MTOR (0.55) | CNR2PIK3CAMTORHTTSMN1; SMN2 | |
| SCHEMBL24393156 | 0.72 | PDE2A (0.62) | CYP1A2PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | CYP17A1 1655/4885CYP1A2 3026/4885PLK4 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.